Harbin Gloria Pharmaceuticals - Asset Resilience Ratio

Latest as of March 2026: 9.04%

Harbin Gloria Pharmaceuticals (002437) has an Asset Resilience Ratio of 9.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002437 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥284.08 Million

≈ $41.57 Million USD Cash + Short-term Investments

Total Assets

CN¥3.14 Billion

≈ $459.71 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Harbin Gloria Pharmaceuticals's Asset Resilience Ratio has changed over time. See Harbin Gloria Pharmaceuticals (002437) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Harbin Gloria Pharmaceuticals's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Harbin Gloria Pharmaceuticals.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥284.08 Million	9.04%
Total Liquid Assets	CN¥284.08 Million	9.04%

Asset Resilience Insights

Limited Liquidity: Harbin Gloria Pharmaceuticals maintains only 9.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Harbin Gloria Pharmaceuticals Industry Peers by Asset Resilience Ratio

Compare Harbin Gloria Pharmaceuticals's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Harbin Gloria Pharmaceuticals (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Harbin Gloria Pharmaceuticals.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	17.02%	CN¥533.66 Million ≈ $78.09 Million	CN¥3.13 Billion ≈ $458.69 Million	+15.96pp
2024-12-31	1.06%	CN¥30.00 Million ≈ $4.39 Million	CN¥2.83 Billion ≈ $413.40 Million	-0.18pp
2022-12-31	1.24%	CN¥50.56 Million ≈ $7.40 Million	CN¥4.07 Billion ≈ $596.18 Million	-7.93pp
2013-12-31	9.17%	CN¥270.00 Million ≈ $39.51 Million	CN¥2.94 Billion ≈ $430.65 Million	+6.05pp
2012-12-31	3.12%	CN¥80.00 Million ≈ $11.71 Million	CN¥2.56 Billion ≈ $375.28 Million	--

pp = percentage points

About Harbin Gloria Pharmaceuticals

SHE:002437 China Drug Manufacturers - Specialty & Generic

Market Cap

$861.43 Million

CN¥5.89 Billion CNY

Market Cap Rank

#9737 Global

#2596 in China

Share Price

CN¥2.64

Change (1 day)

-1.49%

52-Week Range

CN¥2.64 - CN¥4.04

All Time High

CN¥11.06